{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-26-000971","form_type":"8-K","ticker":"BBIO","cik":"0001743881","company_name":"BridgeBio Pharma, Inc.","filed_at":"2026-01-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.055444+00:00","generated_at":"2026-05-16T10:54:32.295538+00:00","sec_items":["2.02","7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"BridgeBio reports Q4 Attruby revenue $146M, cash $587.5M; plans two NDAs in H1 2026","bullets":["Preliminary unaudited Q4 2025 Attruby net revenue $146M; full year $362.4M; cash, equivalents and securities $587.5M as of Dec 31, 2025.","6,629 unique patient prescriptions for Attruby written by 1,632 prescribers as of Dec 31, 2025, reflecting rapid adoption.","New TTR amyloid depleter antibody program to explore ATTR-CM disease reversal; clinic expected between 2027-2028.","FDA recommends NDA for BBP-418 (LGMD2I/R9) toward full approval after positive FORTIFY interim; submission planned H1 2026.","Encumeret NDA for ADH1 planned H1 2026; Phase 3 RECLAIM-HP in chronic hypoparathyroidism to start summer 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-26-000971","json":"https://secwatch.observer/filing/0001140361-26-000971.json","markdown":"https://secwatch.observer/filing/0001140361-26-000971.md","text":"https://secwatch.observer/filing/0001140361-26-000971.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1743881/000114036126000971/0001140361-26-000971-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1743881/000114036126000971/ef20062706_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T10:54:32.295538+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}